Various downstream signaling pathways activated by autocrine adenosine signaling in the tumor immune microenvironment should be considered in the development of promising therapeutic approaches to inhibit CD73 signaling, which may maximize the efficacy of CD73-targeted therapies. Here, NT5E is linked to neoplasm.